Ilumya® (tildrakizumab-asmn)

Ilumya (tildrakizumab-asmn) is covered for adults ≥18 with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (not covered for patients <18 or for non‑FDA indications), dosed per FDA (100 mg SC at weeks 0, 4, then every 12 weeks) with 12‑month approvals. Initial authorization requires dermatologist prescribing/consult and a 3‑month trial or intolerance to at least one systemic or biologic therapy (or a methotrexate contraindication); reauthorization requires ≥3 months on Ilumya with documented clinical (e.g., BSA/erythema/induration/scale) and symptomatic (e.g., decreased pain/itch/burning) improvement.

"Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy."

Sign up to see full coverage criteria, indications, and limitations.